Apart from these two methods, an additional preclinical study showed that cisplatin upregulates the expression of SYT11 (a non-Ca2+ binding synaptic binding protein) and inhibits TAM endocytosis in breast cancer patients, which reduces TAM clearance by tumor cells, a key factor limiting tumor cell sensitivity to cisplatin [59]. This evidence concerns the gene SYT11 and neoplasm.